newsfilter
← Latest News
GlobeNewswire·

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

CANF
  • Can-Fite BioPharma Ltd. announced clinical updates & financial results for the first half of 2026.
  • A Phase 2a study of Namodenoson for advanced pancreatic cancer achieved its primary safety endpoint & demonstrated durable overall survival in heavily pretreated patients.
  • An abstract detailing positive pancreatic cancer results was accepted for presentation at the ESMO Congress 2026, & a Phase IIb study combining chemotherapy with Namodenoson is under development.
  • The pivotal Phase III study of Namodenoson for hepatocellular carcinoma showed blinded overall survival longer than anticipated, prompting an evaluation of an earlier interim analysis.
  • Enrolment of 247 patients was completed in the Phase 3 study of Piclidenoson for psoriasis, which has reached its interim analysis stage with results expected in Q1 2027.
  • The company expanded its intellectual property portfolio with multiple patent allowances in Israel, Canada, Brazil, Australia, & Japan covering therapeutic uses of Namodenoson & Piclidenoson.
  • Revenues for the six months ended June 30, 2026, were $0.20 million, matching the same period in 2025, derived from advance payments under out-licensing agreements.
  • Research & development expenses increased by 13.86% to $3.45 million due to accelerated costs for the Namodenoson & Piclidenoson programs.
  • General & administrative expenses decreased by 31.40% to $1.42 million primarily due to lower investor relations costs.
  • Net loss for the six months ended June 30, 2026, was $4.60 million, a decrease from $4.87 million in the prior year period.
  • Cash & cash equivalents plus short-term deposits totaled $7.03 million as of June 30, 2026, down from $8.53 million at the end of 2025.
  • The company received approximately $4.0 million in aggregate gross proceeds from warrant exercises & inducement in September 2026.
  • Total assets stood at $8.055 million as of June 30, 2026, while total shareholders' equity was $4.855 million.
  • The company maintains a pipeline targeting cancer, liver, & inflammatory diseases with Namodenoson & Piclidenoson, noting Orphan Drug Designation & Fast Track status for Namodenoson in the U.S.